Plasma p-tau217 correlates strongly with cerebrospinal fluid Aβ42 and increases over a ten-year period in amyloid-positive, non-demented very old men
(2025) In Journal of Alzheimer's Disease 108(4). p.1778-1789- Abstract
Background: Plasma phosphorylated tau217 (p-tau217) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highest incidence of AD. Objective: To examine the cross-sectional and longitudinal associations between plasma p-tau217 concentration and cerebrospinal fluid (CSF) AD biomarkers. Further, to investigate the performance of p-tau217 as a predictor of amyloid status in a cohort of very old men. Methods: CSF AD biomarkers were analyzed in thirty-five 89-year-old men. Amyloid-β (Aβ) positivity was defined according to CSF Aβ42 level. Plasma p-tau217... (More)
Background: Plasma phosphorylated tau217 (p-tau217) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highest incidence of AD. Objective: To examine the cross-sectional and longitudinal associations between plasma p-tau217 concentration and cerebrospinal fluid (CSF) AD biomarkers. Further, to investigate the performance of p-tau217 as a predictor of amyloid status in a cohort of very old men. Methods: CSF AD biomarkers were analyzed in thirty-five 89-year-old men. Amyloid-β (Aβ) positivity was defined according to CSF Aβ42 level. Plasma p-tau217 concentration was measured at the mean age of 82, 87, and 91. Incident dementia diagnoses in survivors were identified through medical records up to the age of 102. Results: Plasma p-tau217 strongly correlated with CSF Aβ42 concentration in Aβ-positive (n = 16, Spearman ρ: rho = −0.63, p = 0.009) but not in Aβ-negative (n = 19, rho = 0.111, p = 0.652) men and predicted Aβ status (area under the curve, AUC 0.91). Plasma p-tau217 increased over ten years in the Aβ-positive group, while it remained unchanged in the negative group (p = 0.018). Conclusions: Our findings indicate that plasma p-tau217 is a predictor of brain Aβ deposition also in very old individuals.
(Less)
- author
- organization
- publishing date
- 2025-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, biomarker, cross-sectional, longitudinal, p-tau217, plasma, population-based
- in
- Journal of Alzheimer's Disease
- volume
- 108
- issue
- 4
- pages
- 12 pages
- publisher
- SAGE Publications
- external identifiers
-
- pmid:41160459
- scopus:105023163633
- ISSN
- 1387-2877
- DOI
- 10.1177/13872877251390387
- language
- English
- LU publication?
- yes
- id
- 831646a2-111d-4903-a7aa-fa4663c6bf39
- date added to LUP
- 2026-01-14 13:44:41
- date last changed
- 2026-01-14 13:44:56
@article{831646a2-111d-4903-a7aa-fa4663c6bf39,
abstract = {{<p>Background: Plasma phosphorylated tau<sub>217</sub> (p-tau<sub>217</sub>) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highest incidence of AD. Objective: To examine the cross-sectional and longitudinal associations between plasma p-tau<sub>217</sub> concentration and cerebrospinal fluid (CSF) AD biomarkers. Further, to investigate the performance of p-tau<sub>217</sub> as a predictor of amyloid status in a cohort of very old men. Methods: CSF AD biomarkers were analyzed in thirty-five 89-year-old men. Amyloid-β (Aβ) positivity was defined according to CSF Aβ<sub>42</sub> level. Plasma p-tau<sub>217</sub> concentration was measured at the mean age of 82, 87, and 91. Incident dementia diagnoses in survivors were identified through medical records up to the age of 102. Results: Plasma p-tau<sub>217</sub> strongly correlated with CSF Aβ<sub>42</sub> concentration in Aβ-positive (n = 16, Spearman ρ: rho = −0.63, p = 0.009) but not in Aβ-negative (n = 19, rho = 0.111, p = 0.652) men and predicted Aβ status (area under the curve, AUC 0.91). Plasma p-tau<sub>217</sub> increased over ten years in the Aβ-positive group, while it remained unchanged in the negative group (p = 0.018). Conclusions: Our findings indicate that plasma p-tau<sub>217</sub> is a predictor of brain Aβ deposition also in very old individuals.</p>}},
author = {{Hellquist, Elisabeth and Janelidze, Shorena and Weidung, Bodil and Franzon, Kristin and Giedraitis, Vilmantas and Ingelsson, Martin and Bali, Divya and Velickaite, Vilma and Zetterberg, Henrik and Hansson, Oskar and Kilander, Lena}},
issn = {{1387-2877}},
keywords = {{Alzheimer's disease; biomarker; cross-sectional; longitudinal; p-tau217; plasma; population-based}},
language = {{eng}},
number = {{4}},
pages = {{1778--1789}},
publisher = {{SAGE Publications}},
series = {{Journal of Alzheimer's Disease}},
title = {{Plasma p-tau<sub>217</sub> correlates strongly with cerebrospinal fluid Aβ<sub>42</sub> and increases over a ten-year period in amyloid-positive, non-demented very old men}},
url = {{http://dx.doi.org/10.1177/13872877251390387}},
doi = {{10.1177/13872877251390387}},
volume = {{108}},
year = {{2025}},
}
